Evidence map›Paper›PMID 33780087›Full record

ArticleBrain pathology (Zurich, Switzerland)2021

Serpin neuropathology in the P497S UBQLN2 mouse model of ALS/FTD.

Nicole R Higgins, Jessie E Greenslade, Josephine J Wu, Elena Miranda, Giovanna Galliciotti, Mervyn J Monteiro

Open access · goldAbstract read
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Nicole R HigginsProgram in Molecular Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Jessie E GreensladeCenter for Biomedical Engineering and Technology, Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA.
Josephine J WuCenter for Biomedical Engineering and Technology, Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA.
Elena MirandaDepartment of Biology and Biotechnologies 'Charles Darwin', Pasteur Institute - Cenci Bolognetti Foundation, Sapienza University of Rome, Rome, Italy.
Giovanna GalliciottiInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Mervyn J MonteiroProgram in Molecular Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-1740-5309
University of Maryland, Baltimore · USIstituto Pasteur · ITUniversität Hamburg · DE

Funding

Mechanistic studies and therapeutics for ALS/FTD linked to UBQLN2 mutationsR01NS098243 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI Mervyn J Monteiro · 2017 to 2026
$4.0M
Deciphering the role of ER stress in ALS pathogenesis caused by UBQLN2 mutationsR01NS100008 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI MONTEIRO, MERVYN J · 2017 to 2021
$2.7M
Mechanistic studies and therapeutics for ALS/FTD linked to UBQLN2 mutationsRF1NS098243 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI MONTEIRO, MERVYN J · 2022 to 2022
$2.2M
NINDS NIH HHS R01 NS098243NINDS NIH HHS R01 NS100008NINDS NIH HHS RF1 NS098243
6 · The paper itself

Abstract

Accumulating evidence suggests X-linked dominant mutations in UBQLN2 cause amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD) through both loss- and gain-of-function mechanisms. However, the mechanisms by which the mutations cause disease are still unclear. The goal of the study was to uncover the possible pathomechanism(s) by which UBQLN2 mutations cause ALS/FTD. An analysis of proteomic changes in neuronal tissue was used to identify proteins with altered accumulation in the P497S UBQLN2 transgenic mouse model of ALS/FTD. We then used immunocytochemistry and biochemical techniques to confirm protein changes in the mutant P497S mice. Additionally, we used cell lines inactivated of UBQLN2 expression to determine whether its loss underlies the alteration in the proteins seen in P497S mice. The proteome screen identified a dramatic alteration of serine protease inhibitor (serpin) proteins in the mutant P497S animals. Double immunofluorescent staining of brain and spinal cord tissues of the mutant and control mice revealed an age-dependent change in accumulation of Serpin A1, C1, and I1 in puncta whose staining colocalized with UBQLN2 puncta in the mutant P497S mice. Serpin A1 aggregation in P497S animals was confirmed by biochemical extraction and filter retardation assays. A similar phenomenon of serpin protein aggregation was found in HeLa and NSC34 motor neuron cells with inactivated UBQLN2 expression. We found aberrant aggregation of serpin proteins, particularly Serpin A1, in the brain and spinal cord of the P497S UBQLN2 mouse model of ALS/FTD. Similar aggregation of serpin proteins was found in UBQLN2 knockout cells suggesting that serpin aggregation in the mutant P497S animals may stem from loss of UBQLN2 function. Because serpin aggregation is known to cause disease through both loss- and gain-of-function mechanisms, we speculate that their accumulation in the P497S mouse model of ALS/FTD may contribute to disease pathogenesis through similar mechanism(s).

Indexed as

Adaptor Proteins, Signal TransducingAmyotrophic Lateral SclerosisAnimalsAutophagy-Related ProteinsDisease Models, AnimalFrontotemporal DementiaMiceMice, Inbred C57BLMice, TransgenicMotor NeuronsSerpinsSpinal CordAdaptor Proteins, Signal TransducingAutophagy-Related ProteinsSerpinsUBQLN2 protein, mouseamyotrophic lateral sclerosis (ALS)frontotemporal dementia (FTD)protein aggregationserpinUbiquilin-2 (UBQLN2)

Identifiers

PMID33780087
PMCPMC8387369
OpenAlexW3144306266

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.